Prenatal And Newborn Genetic Testing Market Scope And Analysis

  • Report Code : TIPBT00002550
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Prenatal and Newborn Genetic Testing Market Scope and Analysis Report by 2031

Buy Now


Prenatal and Newborn Genetic Testing Market Report Scope

Report Attribute Details
Market size in 2021 US$ 5.72 Billion
Market Size by 2031 US$ 21.44 Billion
Global CAGR (2023 - 2031) 14.5%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Product
  • Diagnostic
  • Screening
By Disease Indication
  • Cystic Fibrosis
  • Sickle Cell Anaemia
  • Down Syndrome
  • Phenylketonuria
  • Other Diseases
By End User
  • Hospitals & Clinics
  • Diagnostic Centers
  • Other End Users
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Abbott
  • Quest Diagnostics Inc
  • Bio Rad Laboratories Inc
  • Illumina Inc
  • F Hoffmann La Roche Ltd
  • Qiagen
  • PerkinElmer Inc
  • Ravgen
  • Natera Inc
  • Laboratory Corporation of America Holdings
  • Prenatal and Newborn Genetic Testing Market News and Recent Developments

    The prenatal and newborn genetic testing market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for prenatal and newborn genetic testing and strategies:

    • PerkinElmer Inc. received the US Food and Drug Administration authorization for the marketing of the EONIS SCID-SMA assay kit for in vitro diagnostic (IVD) use by certified laboratories for the simultaneous detection of spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) in newborns. This is the first FDA-authorized assay for SMA screening in newborns in the US, and it is part of the company’s broader EONIS Platform. (Source: PerkinElmer Inc., Press Release, 2022)
    • LifeCell International launched 'Genome-Scope' - a premier Genetic Diagnostic Test for newborns that assesses for thousands of early childhood onset disorders. (Source: LifeCell International Private Limited, Press Release, 2020)

    Prenatal and Newborn Genetic Testing Market Report Coverage and Deliverables

    The “Prenatal and Newborn Genetic Testing Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

    • Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope.
    • Market dynamics such as drivers, restraints, and key opportunities
    • Key future trends
    • Detailed PEST/Porter’s Five Forces and SWOT analysis
    • Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
    • Detailed company profiles